Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

This study has been completed.
Information provided by:
Novartis Identifier:
First received: February 23, 2007
Last updated: February 9, 2009
Last verified: January 2009
The purpose of this study is to compare the blood pressure lowering efficacy of valsartan/hydrochlorothiazide (HCTZ) compared to hydrochlorothiazide for the treatment of obese hypertensive (mean sitting systolic blood pressure [MSSBP] >150 mmHg) patients.

Condition Intervention Phase
Drug: HCTZ + Amlodipine
Drug: Valsartan/HCTZ
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A 16-Week Double-Blind, Randomized, Multicenter, Force-Titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change in Mean Sitting Systolic Blood Pressure (MSSBP) [ Time Frame: Baseline to Week 8 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Mean Sitting Diastolic Blood Pressure (MSDBP) [ Time Frame: Baseline to Weeks 4, 8, 12 and 16 ] [ Designated as safety issue: No ]
  • Number of Patients Achieving Blood Pressure (BP) Control by Visit (< 140/90 mm Hg) [ Time Frame: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16) ] [ Designated as safety issue: No ]
  • Number of Patients Achieving Blood Pressure (BP)Control by Visit (< 130/80 mm Hg) [ Time Frame: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16) ] [ Designated as safety issue: No ]
  • Change From Baseline in Postprandial Glucose [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
  • Change From Baseline in Postprandial Insulin [ Time Frame: Week 16 ] [ Designated as safety issue: No ]
  • Change From Baseline in Postprandial Non-Esterified Fatty Acids [ Time Frame: Week 16 ] [ Designated as safety issue: No ]

Enrollment: 412
Study Start Date: December 2006
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: valsartan/HCTZ Drug: Valsartan/HCTZ
  • 160 mg film-coated valsartan tablets
  • 320 mg film-coated valsartan tablets
  • 12.5 mg HCTZ capsules
  • 25 mg HCTZ capsules
Active Comparator: HCTZ +Amlodipine Drug: HCTZ + Amlodipine
  • 12.5 mg HCTZ capsules
  • 25 mg HCTZ capsules
  • 5 mg amlodipine capsules
  • 10 mg amlodipine capsules


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 40 years of age or older
  • Moderate or severe high blood pressure defined as systolic blood pressure (the top number) greater than or equal to 150 mmHg and diastolic blood pressure (the bottom number) less then 110 mmHg
  • Central (abdominal) obesity

Exclusion Criteria:

  • Systolic blood pressure (the top number) greater than or equal to 180 mmHg and diastolic blood pressure (the bottom number) greater than or equal to 110 mmHg
  • Currently taking more then 3 medications to treat high blood pressure
  • Inability to stop all current blood pressure medications if any up to 4 weeks
  • History of Type 1 or Type 2 diabetes
  • History of stroke, mini-stroke (transient ischemic attack) or heart attack within the last 6 months
  • History of or current diagnosis of congestive heart failure
  • History of cancer within the past 5 years with the exception of localized basal cell carcinoma or squamous cell carcinoma
  • Women who are pregnant or nursing
  • Alcohol or drug abuse within the last 2 years

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00439738

United States, Alabama
Terence T. Hart, MD
Muscle Shoals, Alabama, United States, 35662
United States, California
Westlake Medical Research
Westlake Village, California, United States, 91361
United States, Oklahoma
Oklahoma Cardiovascular & Hypertension
Oklahoma City, Oklahoma, United States, 73132
United States, Texas
Northeast Tarrant Internal Medicine Assoc
Euless, Texas, United States, 76040
United States, Washington
Frandsen Family Medicine
Port Orchard, Washington, United States, 98366
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Chair: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00439738     History of Changes
Other Study ID Numbers: CVAH631BUS06 
Study First Received: February 23, 2007
Results First Received: November 5, 2008
Last Updated: February 9, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:
Obesity, hypertension, valsartan/hydrochlorothiazide

Additional relevant MeSH terms:
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Vasodilator Agents processed this record on May 24, 2016